Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells

Chunyu Zhang, Abdel G. Elkahloun, Hongling Liao, Shannon Delaney, Barbara Saber, Betsy Morrow, George C. Prendergast, M. Christine Hollander, Joell Gills, Phillip A. Dennis

Research output: Contribution to journalArticle

Abstract

Activation of the serine/threonine kinase Akt contributes to the formation, maintenance, and therapeutic resistance of cancer, which is driving development of compounds that inhibit Akt. Phosphatidylinositol ether lipid analogues (PIA) are analogues of the products of phosphoinositide-3-kinase (PI3K) that inhibit Akt activation, translocation, and the proliferation of a broad spectrum of cancer cell types. To gain insight into the mechanism of PIAs, time-dependent transcriptional profiling of five active PIAs and the PI3K inhibitor LY294002 (LY) was conducted in non-small cell lung carcinoma cells using high-density oligonucleotide arrays. Gene ontology analysis revealed that genes involved in apoptosis, wounding response, and angiogenesis were upregulated by PIAs, whereas genes involved in DNA replication, repair, and mitosis were suppressed. Genes that exhibited early differential expression were partitioned into three groups; those induced by PIAs only (DUSP1, KLF6, CENTD2, BHLHB2, and PREX1), those commonly induced by PIAs and LY (TRIB1, KLF2, RHOB, and CDKN1A), and those commonly suppressed by PIAs and LY (IGFBP3, PCNA, PRIM1, MCM3, and HSPA1B). Increased expression of the tumor suppressors RHOB (RhoB), KLF6 (COPEB), and CDKN1A (p21Cip1/Waf1) was validated as an Akt-independent effect that contributed to PIA-induced cytotoxicity. Despite some overlap with LY, active PIAs have a distinct expression signature that contributes to their enhanced cytotoxicity.

Original languageEnglish (US)
Pages (from-to)1137-1148
Number of pages12
JournalMolecular Cancer Therapeutics
Volume10
Issue number7
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Phosphatidylinositols
Ether
Lipids
1-Phosphatidylinositol 4-Kinase
Genes
Neoplasms
Gene Ontology
Protein-Serine-Threonine Kinases
Proliferating Cell Nuclear Antigen
Oligonucleotide Array Sequence Analysis
DNA Replication
Mitosis
Non-Small Cell Lung Carcinoma
DNA Repair
Maintenance
Apoptosis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. / Zhang, Chunyu; Elkahloun, Abdel G.; Liao, Hongling; Delaney, Shannon; Saber, Barbara; Morrow, Betsy; Prendergast, George C.; Hollander, M. Christine; Gills, Joell; Dennis, Phillip A.

In: Molecular Cancer Therapeutics, Vol. 10, No. 7, 07.2011, p. 1137-1148.

Research output: Contribution to journalArticle

Zhang, C, Elkahloun, AG, Liao, H, Delaney, S, Saber, B, Morrow, B, Prendergast, GC, Hollander, MC, Gills, J & Dennis, PA 2011, 'Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells', Molecular Cancer Therapeutics, vol. 10, no. 7, pp. 1137-1148. https://doi.org/10.1158/1535-7163.MCT-10-1028
Zhang, Chunyu ; Elkahloun, Abdel G. ; Liao, Hongling ; Delaney, Shannon ; Saber, Barbara ; Morrow, Betsy ; Prendergast, George C. ; Hollander, M. Christine ; Gills, Joell ; Dennis, Phillip A. / Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 7. pp. 1137-1148.
@article{ae69982efc4a495e9b9eaa6784ae5f84,
title = "Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells",
abstract = "Activation of the serine/threonine kinase Akt contributes to the formation, maintenance, and therapeutic resistance of cancer, which is driving development of compounds that inhibit Akt. Phosphatidylinositol ether lipid analogues (PIA) are analogues of the products of phosphoinositide-3-kinase (PI3K) that inhibit Akt activation, translocation, and the proliferation of a broad spectrum of cancer cell types. To gain insight into the mechanism of PIAs, time-dependent transcriptional profiling of five active PIAs and the PI3K inhibitor LY294002 (LY) was conducted in non-small cell lung carcinoma cells using high-density oligonucleotide arrays. Gene ontology analysis revealed that genes involved in apoptosis, wounding response, and angiogenesis were upregulated by PIAs, whereas genes involved in DNA replication, repair, and mitosis were suppressed. Genes that exhibited early differential expression were partitioned into three groups; those induced by PIAs only (DUSP1, KLF6, CENTD2, BHLHB2, and PREX1), those commonly induced by PIAs and LY (TRIB1, KLF2, RHOB, and CDKN1A), and those commonly suppressed by PIAs and LY (IGFBP3, PCNA, PRIM1, MCM3, and HSPA1B). Increased expression of the tumor suppressors RHOB (RhoB), KLF6 (COPEB), and CDKN1A (p21Cip1/Waf1) was validated as an Akt-independent effect that contributed to PIA-induced cytotoxicity. Despite some overlap with LY, active PIAs have a distinct expression signature that contributes to their enhanced cytotoxicity.",
author = "Chunyu Zhang and Elkahloun, {Abdel G.} and Hongling Liao and Shannon Delaney and Barbara Saber and Betsy Morrow and Prendergast, {George C.} and Hollander, {M. Christine} and Joell Gills and Dennis, {Phillip A.}",
year = "2011",
month = "7",
doi = "10.1158/1535-7163.MCT-10-1028",
language = "English (US)",
volume = "10",
pages = "1137--1148",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells

AU - Zhang, Chunyu

AU - Elkahloun, Abdel G.

AU - Liao, Hongling

AU - Delaney, Shannon

AU - Saber, Barbara

AU - Morrow, Betsy

AU - Prendergast, George C.

AU - Hollander, M. Christine

AU - Gills, Joell

AU - Dennis, Phillip A.

PY - 2011/7

Y1 - 2011/7

N2 - Activation of the serine/threonine kinase Akt contributes to the formation, maintenance, and therapeutic resistance of cancer, which is driving development of compounds that inhibit Akt. Phosphatidylinositol ether lipid analogues (PIA) are analogues of the products of phosphoinositide-3-kinase (PI3K) that inhibit Akt activation, translocation, and the proliferation of a broad spectrum of cancer cell types. To gain insight into the mechanism of PIAs, time-dependent transcriptional profiling of five active PIAs and the PI3K inhibitor LY294002 (LY) was conducted in non-small cell lung carcinoma cells using high-density oligonucleotide arrays. Gene ontology analysis revealed that genes involved in apoptosis, wounding response, and angiogenesis were upregulated by PIAs, whereas genes involved in DNA replication, repair, and mitosis were suppressed. Genes that exhibited early differential expression were partitioned into three groups; those induced by PIAs only (DUSP1, KLF6, CENTD2, BHLHB2, and PREX1), those commonly induced by PIAs and LY (TRIB1, KLF2, RHOB, and CDKN1A), and those commonly suppressed by PIAs and LY (IGFBP3, PCNA, PRIM1, MCM3, and HSPA1B). Increased expression of the tumor suppressors RHOB (RhoB), KLF6 (COPEB), and CDKN1A (p21Cip1/Waf1) was validated as an Akt-independent effect that contributed to PIA-induced cytotoxicity. Despite some overlap with LY, active PIAs have a distinct expression signature that contributes to their enhanced cytotoxicity.

AB - Activation of the serine/threonine kinase Akt contributes to the formation, maintenance, and therapeutic resistance of cancer, which is driving development of compounds that inhibit Akt. Phosphatidylinositol ether lipid analogues (PIA) are analogues of the products of phosphoinositide-3-kinase (PI3K) that inhibit Akt activation, translocation, and the proliferation of a broad spectrum of cancer cell types. To gain insight into the mechanism of PIAs, time-dependent transcriptional profiling of five active PIAs and the PI3K inhibitor LY294002 (LY) was conducted in non-small cell lung carcinoma cells using high-density oligonucleotide arrays. Gene ontology analysis revealed that genes involved in apoptosis, wounding response, and angiogenesis were upregulated by PIAs, whereas genes involved in DNA replication, repair, and mitosis were suppressed. Genes that exhibited early differential expression were partitioned into three groups; those induced by PIAs only (DUSP1, KLF6, CENTD2, BHLHB2, and PREX1), those commonly induced by PIAs and LY (TRIB1, KLF2, RHOB, and CDKN1A), and those commonly suppressed by PIAs and LY (IGFBP3, PCNA, PRIM1, MCM3, and HSPA1B). Increased expression of the tumor suppressors RHOB (RhoB), KLF6 (COPEB), and CDKN1A (p21Cip1/Waf1) was validated as an Akt-independent effect that contributed to PIA-induced cytotoxicity. Despite some overlap with LY, active PIAs have a distinct expression signature that contributes to their enhanced cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=79960111315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960111315&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-1028

DO - 10.1158/1535-7163.MCT-10-1028

M3 - Article

C2 - 21551261

AN - SCOPUS:79960111315

VL - 10

SP - 1137

EP - 1148

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -